Former Principia team looks to shake up covalent small molecules again, this time at 'earthquake' scale
Terremoto Biosciences goes back a long ways, in a sense, to about a dozen years ago when Principia Biopharma was founded by UCSF professor Jack Taunton. Peter Thompson initially helmed the biotech.
The company helped expand covalent small molecule inhibitors beyond oncology and into autoimmune disease by targeting cystine. But that amino acid is uncommon in a lot of proteins, offering fewer drug targets than, say, lysine, which is present in most proteins of interest. So, over the years, Taunton went back to the drawing board to check out that second amino acid.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.